2021 Q1 Form 10-Q Financial Statement
#000156459021028189 Filed on May 17, 2021
Income Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| Revenue | $850.0K | $0.00 |
| YoY Change | -100.0% | |
| Cost Of Revenue | $0.00 | |
| YoY Change | -100.0% | |
| Gross Profit | $0.00 | |
| YoY Change | -100.0% | |
| Gross Profit Margin | ||
| Selling, General & Admin | $1.580M | $1.750M |
| YoY Change | -9.71% | 6.06% |
| % of Gross Profit | ||
| Research & Development | $5.510M | $5.409M |
| YoY Change | 1.87% | -27.02% |
| % of Gross Profit | ||
| Depreciation & Amortization | $55.00K | $75.00K |
| YoY Change | -26.67% | 25.0% |
| % of Gross Profit | ||
| Operating Expenses | $7.090M | $5.409M |
| YoY Change | 31.08% | -27.02% |
| Operating Profit | -$6.240M | -$7.159M |
| YoY Change | -12.84% | -21.67% |
| Interest Expense | $332.0K | |
| YoY Change | ||
| % of Operating Profit | ||
| Other Income/Expense, Net | -$2.000K | $10.00K |
| YoY Change | -120.0% | -86.3% |
| Pretax Income | -$6.574M | -$7.149M |
| YoY Change | -8.04% | -21.15% |
| Income Tax | $0.00 | $0.00 |
| % Of Pretax Income | ||
| Net Earnings | -$6.574M | -$7.149M |
| YoY Change | -8.04% | -21.15% |
| Net Earnings / Revenue | -773.41% | |
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$260.5K | -$446.9K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 28.44M | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $29.39M | $2.490M |
| YoY Change | 1080.32% | -77.95% |
| Cash & Equivalents | $29.39M | $2.491M |
| Short-Term Investments | ||
| Other Short-Term Assets | $920.0K | $1.010M |
| YoY Change | -8.91% | 21.69% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | $10.00K | $770.0K |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $30.31M | $4.270M |
| YoY Change | 609.84% | -66.51% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $370.0K | $610.0K |
| YoY Change | -39.34% | 12.96% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | ||
| YoY Change | ||
| Total Long-Term Assets | $370.0K | $610.0K |
| YoY Change | -39.34% | 12.96% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $30.31M | $4.270M |
| Total Long-Term Assets | $370.0K | $610.0K |
| Total Assets | $30.68M | $4.880M |
| YoY Change | 528.69% | -63.28% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $3.250M | $3.300M |
| YoY Change | -1.52% | 35.25% |
| Accrued Expenses | $1.230M | $3.320M |
| YoY Change | -62.95% | -26.55% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $2.290M | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $6.770M | $6.620M |
| YoY Change | 2.27% | -4.89% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $1.134M | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | ||
| YoY Change | ||
| Total Long-Term Liabilities | $1.134M | $0.00 |
| YoY Change | ||
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $6.770M | $6.620M |
| Total Long-Term Liabilities | $1.134M | $0.00 |
| Total Liabilities | $7.903M | $6.620M |
| YoY Change | 19.38% | -4.87% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$284.1M | -$255.8M |
| YoY Change | 11.05% | 13.26% |
| Common Stock | $284.9M | $230.1M |
| YoY Change | 23.82% | 23008700.0% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | $11.00K | $11.00K |
| YoY Change | 0.0% | 0.0% |
| Treasury Stock Shares | ||
| Shareholders Equity | $818.0K | -$25.70M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $30.68M | $4.881M |
| YoY Change | 528.64% | -63.28% |
Cashflow Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$6.574M | -$7.149M |
| YoY Change | -8.04% | -21.15% |
| Depreciation, Depletion And Amortization | $55.00K | $75.00K |
| YoY Change | -26.67% | 25.0% |
| Cash From Operating Activities | -$7.114M | -$7.510M |
| YoY Change | -5.27% | -11.4% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $0.00 | $254.0K |
| YoY Change | -100.0% | |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $0.00 | |
| YoY Change | -100.0% | |
| Cash From Investing Activities | $0.00 | -$254.0K |
| YoY Change | -100.0% | -102.15% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | $31.86M | $5.000M |
| YoY Change | 537.26% | |
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 25.91M | 7.479M |
| YoY Change | 246.4% | |
| NET CHANGE | ||
| Cash From Operating Activities | -7.114M | -7.510M |
| Cash From Investing Activities | 0.000 | -254.0K |
| Cash From Financing Activities | 25.91M | 7.479M |
| Net Change In Cash | 18.79M | -285.0K |
| YoY Change | -6694.04% | -108.57% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$7.114M | -$7.510M |
| Capital Expenditures | $0.00 | $254.0K |
| Free Cash Flow | -$7.114M | -$7.764M |
| YoY Change | -8.37% | -8.4% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2021Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
818000 | |
| CY2021Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-284055000 | |
| CY2021Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
3000 | |
| CY2021Q1 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
1134000 | |
| CY2021Q1 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
11000 | |
| CY2021Q1 | us-gaap |
Liabilities
Liabilities
|
7903000 | |
| CY2021Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
284881000 | |
| CY2020Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-277481000 | |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-26575000 | |
| CY2021Q1 | us-gaap |
Minority Interest
MinorityInterest
|
21963000 | |
| CY2020Q4 | us-gaap |
Minority Interest
MinorityInterest
|
23963000 | |
| CY2021Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-6240000 | |
| CY2020Q4 | us-gaap |
Convertible Debt
ConvertibleDebt
|
8074000 | |
| CY2020Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
13180000 | |
| CY2020Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
1134000 | |
| CY2020Q4 | us-gaap |
Liabilities
Liabilities
|
14314000 | |
| CY2020Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2020Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
3000 | |
| CY2020Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
250914000 | |
| CY2020Q4 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
11000 | |
| CY2020Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-7159000 | |
| CY2021Q1 | us-gaap |
Interest Expense
InterestExpense
|
332000 | |
| CY2021Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-2000 | |
| CY2020Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
10000 | |
| CY2021Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-6574000 | |
| CY2020Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-7149000 | |
| CY2021Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
| CY2020Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
| CY2021Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-6574000 | |
| CY2020Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-7149000 | |
| CY2021Q1 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
0 | |
| CY2020Q1 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
0 | |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6574000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-7149000 | |
| CY2021Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-6574000 | |
| CY2020Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-7149000 | |
| CY2021Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.26 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.45 | |
| CY2021Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
25216788 | |
| CY2020Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
7159000 | |
| CY2021Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
7090000 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
16001023 | |
| CY2019Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-2274000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
7476000 | |
| CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
204000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
4000 | |
| CY2020Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-1739000 | |
| CY2021Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
31863000 | |
| CY2021Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
104000 | |
| CY2021Q1 | us-gaap |
Depreciation
Depreciation
|
55000 | |
| CY2020Q1 | us-gaap |
Depreciation
Depreciation
|
75000 | |
| CY2021Q1 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
176000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
104000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
204000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-130000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
380000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-3000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-387000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-7510000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-254000 | |
| CY2021Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
31863000 | |
| CY2021Q1 | vcnx |
Redemption Of Convertible Debt
RedemptionOfConvertibleDebt
|
5956000 | |
| CY2020Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
4000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
25907000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
7479000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
18793000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-285000 | |
| CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
10596000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
2776000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
29389000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
2491000 | |
| CY2021Q1 | vcnx |
Non Cash Capital Expenditures Incurred But Not Yet Paid
NonCashCapitalExpendituresIncurredButNotYetPaid
|
10000 | |
| CY2020Q1 | vcnx |
Non Cash Capital Expenditures Incurred But Not Yet Paid
NonCashCapitalExpendituresIncurredButNotYetPaid
|
-161000 | |
| CY2020Q1 | vcnx |
Deferred Offering Costs In Prepaid Assets And Accrued Liabilities
DeferredOfferingCostsInPrepaidAssetsAndAccruedLiabilities
|
40000 | |
| CY2020Q1 | vcnx |
Deferred Offering Costs In Accounts Payable And Accrued Expenses
DeferredOfferingCostsInAccountsPayableAndAccruedExpenses
|
253000 | |
| CY2021Q1 | us-gaap |
Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
|
0 | |
| CY2020Q4 | us-gaap |
Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
|
0 | |
| CY2020Q3 | us-gaap |
Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
|
65000 | |
| CY2021Q1 | vcnx |
Royalty Payments Percent Of Net Sales
RoyaltyPaymentsPercentOfNetSales
|
0.01 | |
| CY2021Q1 | vcnx |
Operating Lease Monthly Rental Payments
OperatingLeaseMonthlyRentalPayments
|
14000 | |
| CY2021Q1 | us-gaap |
Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
|
130599 | |
| CY2021Q1 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
145110 | |
| CY2021Q1 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
44000 | |
| CY2020Q1 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
42000 | |
| CY2021Q1 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
3904043 | |
| CY2020Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
3566199 | |
| CY2021Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Such management estimates include those relating to assumptions used in the valuation of stock option awards, and valuation allowances against deferred income tax assets. Actual results could differ from those estimates. </p> | |
| CY2021Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk, Other Risks and Uncertainties </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are deposited in interest-bearing money market accounts. Although the Company deposits its cash with multiple financial institutions, cash balances may occasionally be in excess of the amounts insured by the Federal Deposit Insurance Corporation. Management believes the financial risk associated with these balances is minimal and has not experienced any losses to date.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company depends on third-party manufacturers for the manufacture of drug substance and drug product for clinical trials. The Company also relies on certain third parties for its supply chain. Disputes with these third- party manufacturers or shortages in goods or services from third-party suppliers could delay the manufacturing of the Company’s product candidates and adversely impact its results of operations. </p> | |
| CY2020Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
6880000 | |
| CY2021Q1 | vcnx |
Accrued Clinical Trial Cost Current
AccruedClinicalTrialCostCurrent
|
689000 | |
| CY2020Q4 | vcnx |
Accrued Clinical Trial Cost Current
AccruedClinicalTrialCostCurrent
|
987000 | |
| CY2021Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
446000 | |
| CY2020Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
428000 | |
| CY2021Q1 | us-gaap |
Deferred Offering Costs
DeferredOfferingCosts
|
0 | |
| CY2021Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
7306000 | |
| CY2020Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
7296000 | |
| CY2021Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
6935000 | |
| CY2021Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
59000 | |
| CY2020Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
225000 | |
| CY2021Q1 | vcnx |
Accrued Interest Current
AccruedInterestCurrent
|
10000 | |
| CY2020Q4 | vcnx |
Accrued Interest Current
AccruedInterestCurrent
|
250000 | |
| CY2021Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
25000 | |
| CY2020Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
47000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
15749 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
832868 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
10535 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
827654 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
624737 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
6.83 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
3.40 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
5.00 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
6.82 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
7.53 | |
| CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y10M24D | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y8M12D | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P6Y2M12D | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
2000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
15000 | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
15000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
2.23 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
3.52 | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
230176 | |
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
201702 | |
| CY2021Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
539948 | |
| CY2022Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
628036 | |
| CY2021Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
104000 | |
| CY2020Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
204000 | |
| CY2021Q1 | us-gaap |
Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
|
0 | |
| CY2020Q4 | us-gaap |
Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
|
0 | |
| CY2021Q1 | vcnx |
Number Of Business Activity
NumberOfBusinessActivity
|
1 | |
| CY2021Q1 | vcnx |
Number Of Segment Managers For Operations Or Operating Results
NumberOfSegmentManagersForOperationsOrOperatingResults
|
0 |
